D. Provan

发表

D. Provan, 1999, BMJ.

Recent advances in the mechanisms and treatment of immune thrombocytopenia

J. Semple, D. Provan, 2022, EBioMedicine.

Autologous 111In‐labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry

A. Newland, R. Sobnack, S. Erqou, 2010, British journal of haematology.

The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper

J. Kanis, C. Bradbury, J. Compston, 2019, British journal of haematology.

Treatment practices in adults with chronic immune thrombocytopenia – a European perspective

F. Rodeghiero, M. Michel, D. Provan, 2010, European journal of haematology.

The role of splenectomy in autoimmune hematological disorders: Outdated or still worth considering?

D. Dierickx, S. Vanderschueren, D. Provan, 2017, Blood reviews.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

J. George, J. Bussel, V. Blanchette, 2009, Blood.

Investigational drugs for immune thrombocytopenia

A. Newland, D. Provan, 2022, Expert opinion on investigational drugs.

Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life

J. Bussel, Y. Tomiyama, C. Santoro, 2020, American journal of hematology.

Immune thrombocytopenic purpura in adults

J. Bussel, B. Godeau, D. Provan, 2007, Current opinion in hematology.

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

S. Amadori, A. Newland, R. Stasi, 2006, Rheumatology.

ABC of clinical haematology: Macrocytic anaemias

D. Provan, V. Hoffbrand, 1997, BMJ.

Immune thrombocytopenia – what are the new treatment options?

A. Newland, D. Provan, Simon Hallam, 2013, Expert opinion on biological therapy.

Idiopathic Thrombocytopenic Purpura in Adults

A. Newland, D. Provan, 2003, Journal of pediatric hematology/oncology.

Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.

S. Amadori, A. Newland, R. Stasi, 2005, The oncologist.

ABC of clinical haematology. Iron deficiency anaemia.

D. Provan, R. Frewin, A. Henson, 1997, BMJ.

Helicobacter pylori and Chronic ITP.

R. Stasi, D. Provan, 2008, Hematology. American Society of Hematology. Education Program.

Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura.

S. Amadori, A. Newland, R. Stasi, 2005, The American journal of medicine.

Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline Thrombocytopenia

S. Amadori, A. Newland, R. Stasi, 2006, PLoS medicine.

Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy

W. Ouwehand, I. Greer, M. Murphy, 2003, British journal of haematology.

Red cells II: acquired anaemias and polycythaemia

D. Weatherall, D. Provan, 2000, The Lancet.

Guidelines for immune thrombocytopenia.

A. Newland, D. Provan, 2011, The New England journal of medicine.

Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

J. Bussel, B. Chong, Y. Tomiyama, 2019, Blood advances.

Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic

M. Makris, J. Thachil, M. Laffan, 2020, British journal of haematology.

Management of immune thrombocytopenic purpura in adults.

R. Stasi, D. Provan, 2004, Mayo Clinic proceedings.

CME Haematology – II Wrong environment Wrong genes

D. Provan, 2012 .

Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults

A. Newland, D. Provan, 2002, British journal of haematology.

FIFTY YEARS O F I DIOPATHIC T HROMBOCYTOPENIC P URPURA ( ITP): MANAGEMENT OF R EFRACTORY I TP IN ADULTS

D. Provan, S. Bartholomew, 2002 .

Anti‐CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders

A. Delannoy, G. Verhoef, D. Dierickx, 2011, American journal of hematology.

Myelodysplastic syndrome associated with trisomy 2.

D. Provan, J. Amess, A. Dixon-Mciver, 2005, Clinical and laboratory haematology.

Efficacy of mycophenolate mofetil as single‐agent therapy for refractory immune thrombocytopenic purpura

J. Bussel, A. Newland, D. Provan, 2006, American journal of hematology.

Major Histocompatibility Complex Susceptibility Genes and Immune Thrombocytopenic Purpura in Caucasian Adults

S. Stanworth, D. Turner, A. Newland, 2002, Hematology.

Guidelines on the management of drug‐induced immune and secondary autoimmune, haemolytic anaemia

E. Massey, J. Grainger, D. Provan, 2017, British journal of haematology.

Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.

A. Smith, D. Provan, R. Frewin, 1997, Clinical and laboratory haematology.

primary immune thrombocytopenia International consensus report on the investigation and management of

V. Blanchette, D. Cines, B. Chong, 2010 .

Adult Idiopathic Thrombocytopenic Purpura

A. Mead, A. Newland, D. Provan, 2003, Hematology.

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment

J. Bussel, Y. Tomiyama, C. Santoro, 2020, American journal of hematology.

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

S. Amadori, A. Newland, R. Stasi, 2007, Haematologica.

Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events.

D. Oscier, T. Hamblin, C. Ottensmeier, 2002, Blood.

Novel insights in medical management of immune thrombocytopenia

S. Sivapalaratnam, M. Hanif, D. Provan, 2021 .

Characteristics of immune thrombocytopenic purpura: a guide for clinical practice

D. Provan, 2009, European journal of haematology. Supplementum.

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

J. Logie, A. Newland, A. Shukla, 2010, Haematologica.

Incidence of adult primary immune thrombocytopenia in England—An update

C. Bradbury, M. Makris, Nicola Cooper, 2022, European journal of haematology.

CHAPTER 33 – Acquired disorders affecting megakaryocytes and platelets

A. Newland, D. Provan, P. Maccallum, 2011 .

Rituximab in the treatment of autoimmune haematological disorders

S. Amadori, A. Newland, R. Stasi, 2008, British journal of haematology.

Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta‐analysis

A. Newland, D. Bennett, D. Provan, 2016, European journal of haematology.

Recent progress in understanding the pathogenesis of immune thrombocytopenia

J. Freedman, J. Semple, D. Provan, 2010, Current opinion in hematology.

Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry

S. Wetten, A. Newland, S. Leroy, 2019, European journal of haematology.

Preventing severe infection after splenectomy

A. Newland, S. Myint, D. Provan, 2005, BMJ : British Medical Journal.

Platelets, 2nd Edition

D. Provan, 2007 .

In Vitro Cytotoxic Effects of Stabilizing Sugars within Human Intravenous Immunoglobulin Preparations against the Human Macrophage THP-1 Cell-line

Marc A. Williams, A. Newland, D. Provan, 2003, Hematology.

The diagnosis and management of primary autoimmune haemolytic anaemia

E. Massey, J. Grainger, D. Provan, 2017, British journal of haematology.

International consensus report on the investigation and management of primary immune thrombocytopenia.

Drew Provan, Robert McMillan, Shirley Watson, 2010, Blood.

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

J. Bussel, M. Arning, B. Psaila, 2009, The Lancet.

Thromboembolic Events among Adult Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom General Practice Research Database.

J. Logie, A. Newland, A. Shukla, 2008 .

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

J. Bussel, M. Arning, B. Psaila, 2007, The New England journal of medicine.

A novel missense mutation c.470 A>C (p.D157A) in the SLC40A1 gene as a cause of ferroportin disease in a family with hyperferritinaemia

K. Robson, D. Provan, K. Saja, 2010, British journal of haematology.

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review.

J. Segal, J. Bussel, S. Amadori, 2009, Blood.

Comprar Oxford Handbook of Clinical Haematology | Inderjeet Dokal | 9780199227396 | Oxford University Press

T. Baglin, I. Dokal, D. Provan, 2009 .

Recent advances in haematology

D. O'shaughnessy, D. Provan, D. O'Shaughnessy, 1999, BMJ.

α‐Galactosylceramide‐driven expansion of human natural killer T cells is inhibited by prednisolone treatment

U. Johansson, M. Macey, A. Newland, 2004, British journal of haematology.

Mechanisms and management of iron deficiency anaemia.

D. Provan, 1999, British journal of haematology.

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

J. Gribben, M. Boccadoro, A. Pileri, 1997, Leukemia.

Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation.

J. Gribben, D. Neuberg, J. Ritz, 1996, Blood.

Autoimmune hematological disorders

A. Newland, J. Semple, D. Provan, 2019, Molecular Hematology 4e.

Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes

S. Amadori, A. Newland, R. Stasi, 2005, Leukemia & lymphoma.

Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel

C. Bradbury, J. Thachil, J. Westwood, 2020, Acta Haematologica.

Current Management of Primary Immune Thrombocytopenia

A. Newland, D. Provan, 2015, Advances in Therapy.

United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings

M. Calaminici, A. Newland, D. Bennett, 2015, British journal of haematology.

Sustained Responses following Treatment with Romiplostim in Immune Thrombocytopenia: A Single-Centre Experience

D. Provan, igham, P. Kalkur, 2014 .

Eff ect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura : a randomised , double-blind , placebo-controlled trial

J. Bussel, M. Arning, B. Psaila, 2009 .

Primary Immune Thrombocytopenia

A. Newland, D. Provan, 2010 .

The safety profile of eltrombopag, a novel oral platelet growth factor, in thrombocytopenic patients and healthy subjects.

J. M. Hamilton, R. Rafi, M. Saleh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage

J. Semple, D. Provan, 2012, Current opinion in hematology.

A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia

R. B. Henderson, C. Savage, A. Newland, 2016, Haematologica.

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

M. Steurer, D. Cines, B. Chong, 2017, Haematologica.

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

J. Wasser, B. Godeau, R. Lyons, 2015, International Journal of Hematology.

A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists

C. Bradbury, J. Thachil, M. Murphy, 2018, British journal of haematology.

The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP

J. Bussel, B. Psaila, D. Provan, 2007, British journal of haematology.

Safety of Eltrombopag, an Oral Non-Peptide Platelet Growth Factor, in the Treatment of Thrombocytopenia: Results of Four Randomized, Placebo-Controlled Studies

J. Bussel, J. McHutchison, R. Rafi, 2007 .

Authors' Response to Zimmer et al

S. Amadori, A. Newland, R. Stasi, 2006, PLoS Medicine.

Prescribing intravenous immunoglobulin: summary of Department of Health guidelines

W. Sewell, H. Chapel, D. Provan, 2008, BMJ : British Medical Journal.

Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI)

A. Cuker, N. Bonner, W. Ghanima, 2021, British journal of haematology.

PF712 PHYSICIANS’ PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

J. Bussel, Y. Tomiyama, C. Santoro, 2019, HemaSphere.

Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View

A. Newland, D. Provan, T. González‐López, 2023, Medicina.

Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP)

D. Provan, T. González‐López, 2022, Advances in Therapy.

Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia

Y. Tomiyama, A. Cuker, W. Ghanima, 2021, Advances in Therapy.

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.

A. Bárez, D. Provan, R. Jiménez-Bárcenas, 2023, Blood reviews.

A. Newland, D. Provan, Ameet Sarpatwari, 2008 .

Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults

P. Pharoah, J. Bussel, A. Newland, 2011, Hematology.

Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme

D. Provan, T. González‐López, 2023, Medicina.

The role of splenectomy in autoimmune hematological disorders: Outdated or still worth considering?

D. Dierickx, S. Vanderschueren, D. Provan, 2017, Blood reviews.

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

J. Bussel, M. Arning, B. Psaila, 2009, The Lancet.

Preventing severe infection after splenectomy: Authors' reply

A. Newland, S. Myint, D. Provan, 2005, BMJ : British Medical Journal.

Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel

C. Bradbury, J. Thachil, J. Westwood, 2021, Acta Haematologica.

Primary Immune Thrombocytopenia

A. Newland, D. Provan, 2010 .

. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients With Immune Thrombocytopenia: Results From a Modified

J. Thachil, D. Provan, Nichola Cooper, 2021 .

. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients With Immune Thrombocytopenia: Results From a Modified

J. Thachil, D. Provan, Nichola Cooper, 2021 .

an international working group immune thrombocytopenic purpura of adults and children: report from Standardization of terminology, definitions and outcome criteria in

J. George, J. Bussel, D. Cines, 2009 .

Immune thrombocytopenia

D. Provan, 2013, Hematology.

The diagnosis and management of primary autoimmune haemolytic anaemia

E. Massey, J. Grainger, D. Provan, 2017, British journal of haematology.

A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome

K. Shunnar, D. Provan, A. Rahhal, 2024, Frontiers in Medicine.

The role of T cells and myeloid‐derived suppressor cells in refractory immune thrombocytopenia

K. Yazdanbakhsh, D. Provan, John W. Semple, 2023, British journal of haematology.

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

J. Logie, A. Newland, A. Shukla, 2010, Haematologica.

Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management

J. Thachil, D. Provan, M. Á. Álvarez Román, 2024, Expert review of hematology.

Can Machine Learning Assist in Diagnosis of Primary Immune Thrombocytopenia? A Feasibility Study

D. Provan, Haroon Miah, Dimitrios Kollias, 2024, Diagnostics.

Immune thrombocytopenia – what are the new treatment options?

A. Newland, D. Provan, Simon Hallam, 2013, Expert opinion on biological therapy.

Standardization of Terminology, Definitions and Outcome Criteria in Immune Thrombocytopenic Purpura of Adults and Children: Report from an International Working Group Methodology of the Conference Table 2. Proposed Criteria for Assessing Response to Itp Treatments

D. Cines, M. Mazzucconi, B. Godeau, 2022 .

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently

D. Provan, Salam al Kindi, Mahmoud Marashi, 2023, Frontiers in cardiovascular medicine.